Search clinical trials for: Liraglutide Pen Injector

Total 15708 results

GlaxoSmithKline

Completed

Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

Diabetes Mellitus, Type 2

United States
Leonardo Clavijo
Amgen

Unknown

Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease (Evol-PAD)

Peripheral Arterial Disease

United States
Novo Nordisk A/S

Completed

A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)

Diabetes Mellitus, Type 2

Germany
GlaxoSmithKline

Completed

Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Vanderbilt University Medical Center
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) (GATA-3)

Asthma

United States
Novo Nordisk A/S

Completed

Metabolism and Excretion of Liraglutide in Healthy Male Volunteers

Healthy | Diabetes

Netherlands
University of Colorado, Denver
Novo Nordisk A/S

Recruiting

Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB) (SIB)

Type 2 Diabetes | Chronic Inflammation | Intestinal Permeability

United States
Hospices Civils de Lyon
GlaxoSmithKline

Recruiting

Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices (SECURE)

Asthma

France
University of Nottingham
Medical Research Council

Recruiting

Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets (SemVLCD)

Type 2 Diabetes Mellitus in Obese

United Kingdom
Merck Sharp & Dohme LLC

Completed

Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)

Type 2 Diabetes Mellitus
University Medical Centre Ljubljana

Completed

PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome

Obesity | PCOS

Slovenia
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes

Type 2 Diabetes

China
Henrik Gudbergsen

Completed

Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance (IM-LOSEIT-II)

Obesity | Osteoarthritis

Denmark
Parker Research Institute

Completed

Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis

Osteoarthritis, Knee

Denmark
Henrik Gudbergsen

Completed

Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance (BIO-LOSEIT-II)

Obesity | Osteoarthritis

Denmark
The Deutsche Diabetes Forschungsgesellschaft e.V.
Novo Nordisk A/S; Boehringer Ingelheim; Federal Ministry of Health, Germany; German... and other collaborators

Recruiting

Combined Active Treatment in Type 2 Diabetes With NASH (COMBAT_T2_NASH)

Type 2 Diabetes | Non-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)

Germany, Austria
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

Dercum's Disease

United States
Henrik Gudbergsen
Novo Nordisk A/S; Cambridge Weight Plan Limited

Completed

Liraglutide 3 mg for Knee Osteoarthritis (LOSEIT)

Obesity | Osteoarthritis

Denmark
Henrik Gudbergsen

Completed

Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance (US-LOSEIT-II)

Obesity | Osteoarthritis

Denmark
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-X)

Diabetes Mellitus, Type 2

United States, Brazil, Poland, Russian Federation, Germany, Italy, Netherlands, Spain, Sweden, Argentina, Denmark, Finland, Hungary, Norway, Colombia, Austria, Greece, Puerto Rico
Novo Nordisk A/S

Completed

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus (DUAL™ VIII)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Italy, Mexico, Poland, Russian Federation, Slovakia, United Kingdom, Argentina, Norway, Turkey, Israel, Czechia, South Africa, Hungary, Brazil
University Medical Centre Ljubljana

Completed

Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity

Obesity | Polycystic Ovary Syndrome

Slovenia
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
University Medical Centre Ljubljana

Completed

Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome

Obesity | PCOS

Slovenia
Chen Wei Ren, MD

Unknown

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

Acute Myocardial Infarction

China
Second Affiliated Hospital, School of Medicine,...

Unknown

Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM

Time in Range | T2DM (Type 2 Diabetes Mellitus) | Needle-free Injector

China
Stanford University

Completed

Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood

Inflammation | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset

United States
Novo Nordisk A/S

Completed

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy (DUAL™ III)

Diabetes Mellitus, Type 2 | Diabetes

United States, Slovakia, Hungary, France, Australia
Nanfang Hospital of Southern Medical University

Recruiting

Application of Needle-free Injection of Insulin in Patients With Gestational Diabetes Mellitus

Injection | Gestational Diabetes | Blood Glucose, High | Glycemic Control

China
Novo Nordisk A/S

Completed

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Obesity | Overweight

United States, United Kingdom, Canada, Denmark, Finland, Serbia, Poland, Japan, South Africa, Ireland
Diskapi Teaching and Research Hospital

Completed

Comparison of the Effect of Intra Articular Steroid Injection and Pericapsular Nerve Group Block for Hip Osteoarthritis

Hip Osteoarthritis

Turkey
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Breast Cancer Female

China
Qilu Hospital of Shandong University

Recruiting

Effects of Levosimendan on Cardiac Function After TAVR in Patients With Heart Failure

Heart Failure | Aortic Stenosis, Severe

China
Calibra Medical, Inc.
Northwestern University; University of Texas Southwestern Medical Center; Henry... and other collaborators

Completed

Feasibility Study of Finesse for Bolus Prandial Insulin Dosing Compared to Multiple Daily Injections

Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Comparison of Two Liraglutide Formulations in Healthy Volunteers

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

In-market Utilisation of Liraglutide Used for Weight Management in Europe

Obesity | Metabolism and Nutrition Disorder

Italy, Germany
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Comparison of Three Liraglutide Formulations in Healthy Volunteers

Healthy | Diabetes

Australia
Novo Nordisk A/S

Completed

Comparison of Two Liraglutide Formulations in Healthy Subjects

Healthy | Diabetes

Sweden
Novo Nordisk A/S

Completed

Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers

Healthy | Diabetes

Sweden
Novo Nordisk A/S

Completed

Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes (ROOTS)

Diabetes Mellitus, Type 2 | Diabetes

Belgium
Novo Nordisk A/S

Completed

Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function

Diabetes Mellitus, Type 2 | Diabetes

Australia
Novo Nordisk A/S

Completed

Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers

Healthy | Diabetes

Germany
Stanford University

Not yet recruiting

Clinical Translation of a Novel Brain PET Insert for Simultaneous PET/MR

Brain Disease

United States
Novo Nordisk A/S

Completed

Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice

Diabetes Mellitus, Type 2 | Diabetes

Italy
Novo Nordisk A/S

Completed

Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of
Novo Nordisk A/S

Completed

A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers

Obesity | Metabolism and Nutrition Disorder

Netherlands
Novo Nordisk A/S

Completed

Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes (EVIDENCE)

Diabetes Mellitus, Type 2 | Diabetes

France

Search clinical trials for: Liraglutide Pen Injector

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations